"MCF-7 Cells" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, 
	MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, 
	which enables searching at various levels of specificity.
	
	
		
			
			
				An estrogen responsive cell line derived from a patient with metastatic human breast ADENOCARCINOMA (at the Michigan Cancer Foundation.)
    
			
			
				
				
					
						| Descriptor ID | 
										
							D061986
						 | 			
					
					
						| MeSH Number(s) | 
						
							 A11.251.210.190.630 
						 | 
					
					
						| Concept/Terms | 
						
							MCF-7 Cells- MCF-7 Cells
 - Cell, MCF-7
 - Cells, MCF-7
 - MCF 7 Cells
 - MCF-7 Cell
 - MCF7 Cells
 - Cell, MCF7
 - Cells, MCF7
 - MCF7 Cell
 - Michigan Cancer Foundation 7 Cells
 
  
						 | 
					
					
				
			 
			
				Below are MeSH descriptors whose meaning is more general than "MCF-7 Cells".
				
			 
			
			
				Below are MeSH descriptors whose meaning is more specific than "MCF-7 Cells".
				
			 
		 
	 
 
                                        
                                            
	
	
		
			
			
					
				This graph shows the total number of publications written about "MCF-7 Cells" by people in this website by year, and whether "MCF-7 Cells" was a major or minor topic of these publications. 
				
					
                    To see the data from this visualization as text, 
click here. 
				 
                
		            | Year | Major Topic | Minor Topic | Total | 
|---|
| 2010 | 0 | 1 | 1 | 
| 2012 | 0 | 2 | 2 | 
| 2013 | 0 | 13 | 13 | 
| 2014 | 0 | 19 | 19 | 
| 2015 | 0 | 14 | 14 | 
| 2016 | 0 | 11 | 11 | 
| 2017 | 0 | 13 | 13 | 
| 2018 | 0 | 14 | 14 | 
| 2019 | 0 | 7 | 7 | 
| 2020 | 0 | 11 | 11 | 
| 2021 | 0 | 8 | 8 | 
| 2022 | 0 | 1 | 1 | 
| 2023 | 0 | 1 | 1 | 
| 2024 | 0 | 2 | 2 | 
| 2025 | 0 | 1 | 1 | 
                    To return to the timeline, 
click here.
                 
			 	
			
			
			
			
				Below are the most recent publications written about "MCF-7 Cells" by people in Profiles.
						
					
								- 
								
ESR1 Y537S and D538G Mutations Drive Resistance to CDK4/6 Inhibitors in Estrogen Receptor-Positive Breast Cancer. Clin Cancer Res. 2025 May 01; 31(9):1667-1675.
															
								 
							
								- 
								
Inhibition of microRNA-660-5p decreases breast cancer progression through direct targeting of TMEM41B. Hereditas. 2024 Dec 21; 161(1):53.
															
								 
							
								- 
								
Evidence that CRISPR-Cas9 Y537S-mutant expressing breast cancer cells activate Yes-associated protein 1 to driving the conversion of normal fibroblasts into cancer-associated fibroblasts. Cell Commun Signal. 2024 Nov 14; 22(1):545.
															
								 
							
								- 
								
Flexible fluorine-thiol displacement stapled peptides with enhanced membrane penetration for the estrogen receptor/coactivator interaction. J Biol Chem. 2024 Dec; 300(12):107991.
															
								 
							
								- 
								
Synergistic Cytotoxicity of Histone Deacetylase and Poly-ADP Ribose Polymerase Inhibitors and Decitabine in Breast and Ovarian Cancer Cells: Implications for Novel Therapeutic Combinations. Int J Mol Sci. 2024 Aug 26; 25(17).
															
								 
							
								- 
								
A drug repurposing study identifies novel FOXM1 inhibitors with in vitro activity against breast cancer cells. Med Oncol. 2024 Jun 25; 41(8):188.
															
								 
							
								- 
								
MicroRNA regulation of the serine synthesis pathway in endocrine-resistant breast cancer cells. Endocr Relat Cancer. 2023 11 01; 30(11).
															
								 
							
								- 
								
Irreversible HER2 inhibitors overcome resistance to the RSL3 ferroptosis inducer in non-HER2 amplified luminal breast cancer. Cell Death Dis. 2023 08 18; 14(8):532.
															
								 
							
								- 
								
Regulatory mechanisms and function of hypoxia-induced long noncoding RNA NDRG1-OT1 in breast cancer cells. Cell Death Dis. 2022 09 20; 13(9):807.
															
								 
							
								- 
								
Targeting CDK7 reverses tamoxifen resistance through regulating stemness in ER+ breast cancer. Pharmacol Rep. 2022 Apr; 74(2):366-378.